From BigGo Finance · BigGo Finance · · 1m 10s
Hana Securities Targets Celltrion at 310,000 Won
Hana Securities boosts Celltrion stock with 310,000 won target, betting on U.S. biosimilar sales growth.
In brief
Hana Securities boosts Celltrion stock with 310,000 won target, betting on U.S. biosimilar sales growth. Hana Securities initiates Celltrion coverage with a 310,000 won target, citing U.S. biosimilar sales as growth driver. Originally reported by BigGo Finance.
Hana Securities Initiates Coverage

Hana Securities has initiated coverage on South Korea's Celltrion with a 'Buy' rating and a target price of 310,000 won.
Q3 Revenue and Profit Growth
Third-quarter revenue rose 53.1% year-over-year to 1.5755 trillion won, with operating profit up 74.3% to 525.3 billion won.
U.S. Direct Sales Catalyst
Direct sales in the U.S. are driving growth, with five newly launched products improving profitability.
Full-Year Projections

Full-year revenue projected at 5.8478 trillion won, exceeding company guidance by 40.5%.
U.S. Healthcare Policy Impact
Democrats securing Senate and House control in midterm elections may boost biosimilar demand through Medicaid expansion.
Eli Lilly Contract Manufacturing
Celltrion earns contract manufacturing revenue from Eli Lilly after acquiring the Branchburg plant in the U.S.
Stock Outlook
Celltrion stock could surpass previous high if U.S. biosimilar sales continue to grow.
The big picture
Hana Securities initiates Celltrion coverage with a 310,000 won target, citing U.S. biosimilar sales as growth driver.
Read the TL;DR — this story on one card.





